With flurry of FAA approvals, drones are about to fly much farther over US skies
A rendering of P2 Zips charging at a docking station.
Zipline
This week, drone delivery company Zipline was granted Federal Aviation Administration approval to fly drones beyond the visual line of sight. That’s a major milestone in efforts to extend the range of the domestic drone industry over U.S. airspace, and Zipline isn’t the only drone operator to recently receive FAA approval.
In a series of moves in August and earlier in September, the FAA gave the same clearance to UPS subsidiary Flight Forward (which delivers packages by drone), avionics provider uAvionix, and drone inspection provider Phoenix Air Unmanned. It’s a regulatory aim that the drone companies have been working towards for a decade and will pave the way for other companies to receive streamlined approval for their own drone flights beyond the visual line of sight, as well as for more consumer companies to accelerate efforts to deliver goods by unmanned aircraft.
The FAA told aviation publication Flying that the approvals will serve as the basis for “summary grants” in the future as it continues to work towards formal rulemaking and to help fast track business models similar to the ones to receive the first approvals, meaning package delivery, drone inspections, medical supplies and drone aviation system development, such as uAvionix.
Prior to “beyond the visual line of sight” approval, human observers were required to be stationed along the entire route a drone was flying to ensure that there was no interference with air traffic. The new regulations allow for drones to be flown without observers, which the companies say will increase accessibility and scalability of what’s still a nascent business in the U.S.
“For the last few years, we’ve been operating in the U.S. with training wheels,” said Zipline CEO Keller Cliffton. “We were able to make deliveries to homes but we always needed to stay within a mile-and-a-half of our distribution centers, which made it easy to serve tens of thousands of people, but impossible to serve hundreds of thousands of people.”
Now he says Zipline will be able to serve “hundreds of millions of people” in the U.S.
“It unlocks the scale of the technology so that everybody can benefit. And, at scale, this technology will save people a lot of money, and it will also save lives in the U.S.,” said Cliffton, whose company began in 2014 as a drone solution for emergency medical deliveries in hard-to-reach geographies but has expanding into multiple sectors and has deals with retailers including Walmart.
In March, Zipline released its drone Platform 2, or P2 Zip, which can carry up to eight pounds within a ten-mile radius, finish flights in about ten minutes, and land a package on a space as small as a table or doorstep.
“The reason that number is important is that when you look at e-commerce in the U.S., a vast majority of packages weigh five pounds or less,” Cliffton said in a conversation with CNBC about the new drones in March. As far back as 2020, the company was part of drone tests with Walmart in Arkansas. Early this year, Walmart announced that with partners including Zipline, DroneUp and Flytrex, it had grown to 36 drone delivery hubs across Arizona, Arkansas, Florida, North Carolina, Texas, Utah and Virginia.
The FAA approvals mean the regulator is satisfied that the drones can safely operate with autonomous technology to monitor airspace and avoid aircraft that they may encounter. Zipline’s drone programming enacts 500 preflight safety checks and has an acoustic avoidance system, though was still unable to fly beyond the line of sight until it received FAA approval.
The list of products that Zipline — a five-time CNBC Disruptor 50 company that ranked No. 25 on this year’s list — is flying since it started as a medical care supplier in Rwanda has grown to include food deliveries, prescriptions, agriculture products, retail items, and medical supplies for both humans and animals.
“Approval of an onboard perception system that enables beyond visual line of sight flight has been the holy grail for drone delivery for the last 10 years,” Cliffton said.
And he says there are global implications of the long-awaited U.S. decision.
“Both the FAA and Congress know that it is really strategically important for the U.S. to stay in the lead when it comes to this fundamental technological transformation that’s happening, where it’s suddenly now possible to build the first logistics systems that are fully zero emission and automated,” he said.
“I think some people have seen how much other countries were growing on this front and thought maybe the U.S. was going to fall behind, and I think this is an exciting demonstration that the U.S. may be a fast follower of a few other countries, but that in general, the U.S. is going to be a global leader when it comes to this industry.”
Anne Wojcicki attends the WSJ Magazine Style & Tech Dinner in Atherton, California, on March 15, 2023.
Kelly Sullivan | Getty Images Entertainment | Getty Images
23andMe CEO Anne Wojcicki and New Mountain Capital have submitted a proposal to take the embattled genetic testing company private, according to a Friday filing with the U.S. Securities and Exchange Commission.
Wojcicki and New Mountain have offered to acquire all of 23andMe’s outstanding shares in cash for $2.53 per share, or an equity value of approximately $74.7 million. The company’s stock closed at $2.42 on Friday with a market cap of about $65 million.
The offer comes after a turbulent year for 23andMe, with the stock losing more than 80% of its value in 2024. In January, the company announced plans to explore strategic alternatives, which could include a sale of the company or its assets, a restructuring or a business combination.
23andMe has a special committee of independent directors in place to evaluate potential paths forward. The company appointed three new independent directors to its board in October after all seven of its previous directors abruptly resigned the prior month. The special committee has to approve Wojcicki and New Mountain’s proposal.
“We believe that our Proposal provides compelling value and immediate liquidity to the Company’s public stockholders,” Wojcicki and Matthew Holt, managing director and president of private equity at New Mountain, wrote in a letter to the special committee on Thursday.
Wojcicki previously submitted a proposal to take the company private for 40 cents per share in July, but it was rejected by the special committee, in part because the members said it lacked committed financing and did not provide a premium to the closing price at the time.
Wojcicki and New Mountain are willing to provide secured debt financing to fund 23andMe’s operations through the transaction’s closing, the filing said. New Mountain is based in New York and has $55 billion of assets under management, according to its website.
23andMe declined to comment.
WATCH: The rise and fall of 23andMe
Hims & Hers
Shares of Hims & Hers Health tumbled more than 23% on Friday after the U.S. Food and Drug Administration announced that the shortage of semaglutide injection products has been resolved.
Semaglutide is the active ingredient in Novo Nordisk‘s blockbuster weight loss drug Wegovy and diabetes treatment Ozempic. Those medications are part of a class of drugs called GLP-1s, and demand for the treatments has exploded in recent years. As a result, digital health companies such as Hims & Hers have been prescribing compounded semaglutide as an alternative for patients who are navigating volatile supply hurdles and insurance obstacles.
Compounded drugs are custom-made alternatives to brand-name drugs designed to meet a specific patient’s needs, and compounders are allowed to produce them when brand-name treatments are in shortage. The FDA doesn’t review the safety and efficacy of compounded products.
Hims & Hers began offering compounded semaglutide to patients in May, and it owns compounding pharmacies that produce the medications.
Compounded medications are typically much cheaper than their branded counterparts. Hims & Hers sells compounded semaglutide for less than $200 per month, while Ozempic and Wegovy both cost around $1,000 per month without insurance.
The FDA said Friday that it will start taking action against compounders for violations in the next 60 to 90 days, depending on the type of facility, in order to “avoid unnecessary disruption to patient treatment.”
“Now that the FDA has determined the drug shortage for semaglutide has been resolved, we will continue to offer access to personalized treatments as allowed by law to meet patient needs,” Hims & Hers CEO Andrew Dudum posted Friday on X. “We’re also closely monitoring potential future shortages, as Novo Nordisk stated two weeks ago that it would continue to have ‘capacity limitations’ and ‘expected continued periodic supply constraints and related drug shortage notifications.'”
Him & Hers’ weight loss offerings have been a massive hit with investors. Shares of the company climbed more than 200% last year, and the stock is already up more than 100% this year despite Friday’s move.
Even before it added compounded GLP-1s to its portfolio, the company said in its 2023 fourth-quarter earnings call that it expects its weight loss program to bring in more than $100 million in revenue by the end of 2025.
Despite the turbulent regulatory landscape, Hims & Hers has showed no signs of slowing down.
On Friday, the company announced it has acquired a U.S.-based peptide facility that will “further verticalize the company’s long-term ability to deliver personalized medications.” Hims & Hers will explore advances across metabolic optimization, recovery science, biological resistances, cognitive performance and preventative health through the acquisition, the company said.
That move comes just days after Hims & Hers also bought Trybe Labs, the New Jersey-based at-home lab testing facility. Trybe Labs will allow Hims & Hers to perform at-home blood draws and more comprehensive pretreatment testing.
Hims & Hers did not disclose the terms of either deal.
Technology
Tesla recalls more than 375,000 vehicles in U.S. due to failing power-assisted steering systems
Tesla models Y and 3 are displayed at a Tesla dealership in Corte Madera, California, on Dec. 20, 2024.
Justin Sullivan | Getty Images
Tesla is voluntarily recalling 376,241vehicles in the U.S. to correct an issue with failing power-assisted steering systems, according to records posted to the website of the U.S. National Highway Traffic Safety Administration.
In a safety recall report posted on the NHTSA website, Tesla said the recall includes Model 3 and Model Y vehicles that were manufactured for sale in the U.S. from Feb. 28, 2023, to October 11, 2023, and that were equipped with a certain older software release.
The records said printed circuit boards in the steering systems in affected vehicles could become overstressed, causing the power-assist steering to fail in some cases when a Tesla vehicle rolled to a stop and then accelerated.
When electronic power-assist steering systems fail in a Tesla, drivers need to exert more force to steer their cars, which can increase the risk of a collision.
Tesla told the vehicle safety regulator that it was not aware of any crashes, injuries or deaths related to the power steering failures, and that it was offering an over-the-air software update as a remedy.
The recall follows an earlier related probe and voluntary recall in China concerning the same systems.
President Donald Trump has appointed Tesla CEO Elon Musk to lead a team that is slashing the federal government workforce, and in some cases, regulations and entire agencies. Those cuts already affected the NHTSA, an agency Musk has long seen as standing in the way of some of his ambitions at Tesla.
The regulator has been engaged in a yearslong investigation into safety defects in the systems that Tesla markets currently as its Autopilot and Full Self-Driving (Supervised) options. The features do not make Tesla cars into robotaxis. They require a human driver ready to steer or brake at any time.
The Washington Post reported on Thursday that Musk’s team has led mass firings at the NHTSA, reducing the agency’s workforce and capacity to investigate companies including Tesla by about 10%.
Tesla didn’t respond to a request for comment.
-
Sports2 years ago‘Storybook stuff’: Inside the night Bryce Harper sent the Phillies to the World Series
-
Sports11 months agoStory injured on diving stop, exits Red Sox game
-
Sports1 year agoGame 1 of WS least-watched in recorded history
-
Sports2 years agoMLB Rank 2023: Ranking baseball’s top 100 players
-
Sports3 years ago
Team Europe easily wins 4th straight Laver Cup
-
Environment2 years agoJapan and South Korea have a lot at stake in a free and open South China Sea
-
Environment2 years agoGame-changing Lectric XPedition launched as affordable electric cargo bike
-
Business2 years agoBank of England’s extraordinary response to government policy is almost unthinkable | Ed Conway